Back to Search
Start Over
Pharmaceutical proteins in plants. A strategic genetic engineering approach for the production of tuberculosis antigens
- Source :
- Annals of the New York Academy of Sciences, Annals of the New York Academy of Sciences, Wiley, 2008, 1149, pp.275-80. ⟨10.1196/annals.1428.089⟩, Annals of the New York Academy of Sciences 1149 (2008): 275–280. doi:10.1196/annals.1428.089, info:cnr-pdr/source/autori:Frutos R., Denise H., Vivares C., Neuhaus J.M., Vitale A., Pedrazzini E., Ma J., Dix P., Gray J., Pezzotti M., Conrad U., Robinson D. (2008)/titolo:Pharmaceutical proteins in plants. A strategic genetic engineering approach for the production of tuberculosis antigens/doi:10.1196%2Fannals.1428.089/rivista:Annals of the New York Academy of Sciences/anno:2008/pagina_da:275/pagina_a:280/intervallo_pagine:275–280/volume:1149, Annals of the New York Academy of Sciences, 2008, 1149, pp.275-80. ⟨10.1196/annals.1428.089⟩
- Publication Year :
- 2008
- Publisher :
- HAL CCSD, 2008.
-
Abstract
- International audience; Tuberculosis (TB) is a re-emerging disease that is considered a major human health priority as well as an important disease of livestock. TB is also a zoonosis, and Mycobacterium tuberculosis and M. bovis, the human and bovine causative agents, respectively, are very closely related. Protection against TB is essentially achieved through vaccination with the Bacille Calmetle-Guerin (BCG) strain of M. bovis. Protection is, however, incomplete, and novel improved vaccines are currently under investigation. Production of protective antigens in transgenic plants, or "pharming," is a promising emerging approach, and a zoonosis-like TB is a good model for investigating the potential of this approach. Pharma-Planta, a European Commission-funded project and consortium, was set up to address this topic, within which a component is aimed at assessing the production efficacy and stability of the TB antigens in different compartments of the plant cell. This article is meant to introduce this promising approach for veterinary medicine by describing the ongoing project and its specific genetic engineering strategy.
- Subjects :
- MESH: Mycobacterium bovis
MESH: Mycobacterium tuberculosis
Vaccin
MESH: Transgenes
plant biotechnology
L73 - Maladies des animaux
Projet de recherche
Antigène
Tuberculose
Transgenes
Plant Proteins
Génie génétique
Antigens, Bacterial
tuberculosis
vaccines
pharming
Pharma-Planta
MESH: Plant Proteins
Mycobacterium tuberculosis
Plante transgénique
Mycobacterium bovis
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology
MESH: Genetic Engineering
Genetic Engineering
Protéine végétale
MESH: Antigens, Bacterial
Subjects
Details
- Language :
- English
- ISSN :
- 00778923 and 17496632
- Database :
- OpenAIRE
- Journal :
- Annals of the New York Academy of Sciences, Annals of the New York Academy of Sciences, Wiley, 2008, 1149, pp.275-80. ⟨10.1196/annals.1428.089⟩, Annals of the New York Academy of Sciences 1149 (2008): 275–280. doi:10.1196/annals.1428.089, info:cnr-pdr/source/autori:Frutos R., Denise H., Vivares C., Neuhaus J.M., Vitale A., Pedrazzini E., Ma J., Dix P., Gray J., Pezzotti M., Conrad U., Robinson D. (2008)/titolo:Pharmaceutical proteins in plants. A strategic genetic engineering approach for the production of tuberculosis antigens/doi:10.1196%2Fannals.1428.089/rivista:Annals of the New York Academy of Sciences/anno:2008/pagina_da:275/pagina_a:280/intervallo_pagine:275–280/volume:1149, Annals of the New York Academy of Sciences, 2008, 1149, pp.275-80. ⟨10.1196/annals.1428.089⟩
- Accession number :
- edsair.pmid.dedup....ac2e1a70a558b78970db52c4435ea0ea